On the one hand, AMPK inhibits mTORC1, and on the other hand, it collaborates with PPARα to reduce the expression of key enzymes of glycolipid and glutamine metabolism and inhibit glycolytic, thus specifically killing tumor cells [31,32]. The gene discussed is PPARA; the disease is neoplasm.